Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.
Drug-tolerant persisters, de novo mutations and pre-existing resistance are just some of the ways cancers evade the effects of anti-cancer drugs. Can new targets and new dosing strategies tackle evolutionary forces directly to delay the inevitable?
A massive, pioneering trial is underway to assess whether RNA-based modulation of Lp(a) — a form of bad cholesterol that narrows arteries, boosts the risk of blood clots and fans the flames of inflammation — can save lives.
Immunotherapies that activate costimulatory receptors on T cells have failed so far in the clinic, but the first phase III trial of an agonist antibody in cancer has just begun and second-generation candidates are advancing.
Nearly ten compounds from zebrafish screens are in or about to enter the clinic, and zebrafish 'avatars' are gaining traction as a tool to guide treatment plans for patients with cancers and rare diseases.
Recursion, Janssen, insitro and others are combining high-content phenotypic screening with machine learning to zoom in on emerging opportunities in target discovery, hit identification, toxicity testing and more.
A long and growing list of anti-BCMA candidates — including chimeric antigen receptor-T cell therapies, antibody–drug conjugates and bispecific antibodies — are contending to transform multiple myeloma treatment.
Inhibitors of the innate immune system’s NLRP3 inflammasome promise potential in Parkinson disease, Alzheimer disease, non-alcoholic steatohepatitis, gout and much more, catching the eye of Novartis, Genentech and others.
From branded generics to drugs developed specifically for patients in Asia, Bethan Hughes investigates the strategies that large-cap pharmaceutical companies are pursuing to meet the medical needs of emerging markets.